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Abstract: In this work, three novel silver(I) complexes with an almost com-
pletely rigid and bulky monodentate ligand, 1-adamantanamine, were synthe-
sized. The aliphatic amine, 1-adamantanamine, is the sole electron donor ligand 
in these complexes. In addition to spectroscopic characterization, the basic bio-
logical activities of the new compounds were investigated and their minimum 
inhibitory concentrations were determined. The antifungal and antibacterial 
activities indicate that these compounds could potentially be applied as new 
therapeutics. 
Keywords: amantadine; silver(I) complexes; rigid and bulky ligand; NMR 
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INTRODUCTION 
Adamantane is a hydrocarbon that consists of three connected cyclohexane 
rings, forming a cage-like structure. Although there are numbers of isomers with 
the formula C10H16, adamantane is the most stable one.1 Moreover, it is peculiar 
since it is rigid considering its “armchair” configuration, but practically without 
strain. The lipophilic adamantyl group is interesting from the aspect of medicinal 
chemistry, since it is present in several compounds that are currently used for the 
treatment of neurodegenerative disorders, viral infections and type 2 diabetes.2 
Adamantane polymers have been patented as antiviral agents against HIV.3 It is 
important to emphasize that in many cases, the adamantyl group has improved 
the pharmacological properties of a parent compound, without increasing the 
toxicity.  
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Different derivatives of adamantane, such as memantine, dopamantine and 
rimantadine have been utilized as therapeutics. Amantadine (1-adamantanamine), 
which can be obtained in a well-established way from adamantane,4–6 was used 
as an antiviral drug against different strains of influenza7 and in the treatment of 
Parkinson’s disease.8,9  
It is well known that ligands having electron-donating atom(s) often show 
increased cytotoxicity due to their enhanced coordination capacity.10,11 Various 
research groups are devoted to development of novel coordination compounds 
that contain 1-adamantanamine as a ligand in order to improve the performances 
and potentially overcome the shortcomings of known therapeutics. So far, plati-
num, titanium and zinc complexes with adamantylamine ligand were synthe-
sized, characterized and studied from the perspectives of therapy and biological 
interest.12–15 For example, platinum(IV) complexes with adamantylamine were 
thoroughly tested for their biological activity and have the potential to provide a 
significantly improved therapy for many types of tumors.13  
To the best of our knowledge, a complex of 1-adamantanamine with silver(I) 
has not been described, although some similar compounds could be found in the 
literature.16 In addition, in these complexes, 1-adamantanamine is the sole elec-
tron donor ligand. Since silver(I) ion is very well recognized for its antibacterial 
activity,17 three novel silver(I) complexes with bulky, rigid 1-adamantanamine 
ligand were synthesized and characterized by spectroscopic measurements. The 
antifungal and antibacterial activities of these compounds were investigated and 
their minimum inhibitory concentrations were determined.  
EXPERIMENTAL 
An appropriate silver(I) salt was added dropwise during 30 min under stirring to a 
methanolic solution of 1-adamantanamine. The mixture was stirred for 2 h in total darkness. 
The mole ratio of the reactants was 2.1:1 in favor of the amine. The obtained clear solution 
was left to crystallize for 72 h in the dark. The formed photosensitive crystals were suction-fil-
tered in the dark and dried in a light-protected desiccator. The synthetic procedure can be 
summarized by Scheme 1. 
 
Scheme 1. Overall synthesis of the silver(I) complexes. 
Total silver content for the three novel compounds was determined by means of the 
atomic absorption method EPA 272.1, direct aspiration. The infrared (IR) spectra were rec-
orded in the wavenumber range 4000–480 cm-1 on a Nicolet 6700 FT-IR instrument (Thermo 
Scientific) using the KBr technique. The 1H-NMR spectra were recorded on a Varian Gemini 
2000 instrument at 200 MHz and the 13C-NMR spectra were recorded on a Bruker Avance III 
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instrument at 50 MHz. The agar-dilution method18 was used for the determination of the 
minimal inhibitory concentration (MIC) values of the synthesized complexes. The microorg-
anisms were prepared in nutrient-rich agar plates without the tested substances to obtain single 
cell colonies, which were then transferred into nutrient-rich agar plates containing the tested 
substances (10 μL, range: 0.02 to 50 μmol L-1). The inoculated agar-plates were incubated for 
24 h and then the colonies were counted. 
RESULTS AND DISCUSSION 
Three novel silver(I) complexes, bis(1-adamantanamine)silver(I) nitrate 
hemimethanolate, bis(1-adamantanamine)silver(I) perchlorate hemimethanolate 
and bis(1-adamantanamine)silver(I) D-camphor-10-sulphonate hemipentametha-
nolate (Fig. 1), were synthesized and characterized by atomic absorption, IR and 
1H- and 13C-NMR measurements.  
 
Fig. 1. The presumed structure of bis(1-adamantanamine)silver(I) D-camphor-10-sulphonate. 
Elemental microanalysis measurements are not reliable for this type of com-
pounds, since the studied complexes showed incomplete combustion. Moreover, 
reported sublimation and vaporization enthalpies showed significant discrep-
ancies.19–24 The highly symmetric, globular ligand, 1-adamantanamine, shows a 
tendency to sublime. In order to determine accurately the combustion enthalpy of 
adamantane, its derivatives and complexes, the samples should be combusted in a 
calorimetric bomb under high pressure.25 Thus, atomic absorption measurements 
were performed as a substitute. The calculated value for the total silver in bis(1-
adamantanamine)silver(I) nitrate hemimethanolate is 22.09 %, while the deter-
mined value was 21.9±0.1 %. In the case of bis(1-adamantanamine)silver(I) 
perchlorate hemimethanolate, the calculated value for the total silver is 20.51 % 
and the determined value was 20.56±0.1 %. For the bis(1-adamantanamine)sil-
ver(I) D-camphor-10-sulphonate complex, the calculated and determined values 
were 14.94 % ([Ag(1-AdNH2)2]CSA·2.5CH3OH) and 14.77± 0.1 %, respectively.  
The infrared spectrum of 1-adamantanamine showed characteristic bands for 
primary amines: asymmetric and symmetric stretching bands (NH2 group) at 
3329.8 and 3252.7 cm–1, respectively, N–H bend vibrations at 1587.7 cm–1, C–N 
stretch (aliphatic amines) in the region of 1250–1020 cm–1, located at 1098.8 cm–1, 
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and N–H wag vibration was found at 812.2 cm–1. Moreover, in this spectrum two 
strong bands were observed at 2907.5 and 2848.7 cm–1, presenting asymmetric 
and symmetric stretching bands, respectively (CH and CH2 groups). In the IR 
spectrum of the synthesized complex of 1-adamantanamine with silver nitrate, 
the following bands were observed: 3435.2 cm–1, wide stretching band; 1591.4 
cm–1, weak bending band that arises from the NH2 group; 1348.1 cm–1, strong 
stretching band of the NO3– ion; 2910.6 and 2847.1 cm–1, strong stretching 
bands originating from the CH2 groups and 1450.7 cm–1, weak bending band, 
which is derived from the CH groups. In the IR spectrum of the synthesized 
complex of 1-adamantanamine with silver camphorsulfonate, the following 
bands were registered: 3457.1 cm–1, wide stretching band; 1597.3 cm–1, weak 
bending band originating from the NH2 group; 2903.5 and 2846.5 cm–1, strong 
stretching bands that originate from the CH2 groups, 1451.6 and 1367.7 cm–1, 
weak bending bands that originate from the CH groups; 1740.6 cm–1, strong 
stretching band that comes from the C=O group; 1197.6 and 1047.0 cm–1 strong 
bands of the SO3– group. In the IR spectrum of the synthesized complex of 
1-adamantanamine with silver perchlorate, the following bands were detected: 
3426.0 cm–1, wide stretching band; 1584.2 cm–1, weak bending band that ori-
ginates from the NH2 group; 1097.0 and 621.5 cm–1 strong stretching bands that 
arise from ClO4–, 2906.7 and 2846.5 cm–1, strong stretching bands that come 
from the CH2 group and 1450.7 and 1363.6 cm–1, weak bending bands origin-
ating from the CH group. Due to relatively low concentration of methanol, its IR 
bands were overlapped with the bands that belong to the NH2 and CH2 groups 
and counter ions.  
In summary, two peaks assigned to stretching modes of NH2 group (3329.8 
and 3252.7 cm–1) in the non-coordinated ligand had become one broad peak 
located around 3440 cm–1 in the spectra of all the investigated complexes, indi-
cating that the coordination to the metal ion was successful.  
Evidence for complexation of silver(I) to l-adamantanamine could also be 
obtained from the NMR spectra. In the 1H-NMR spectrum of l-adamantanamine, 
two broad signals of carbon-bound hydrogen atoms could be seen – one at 2.05 
ppm, corresponding to the methine protons, and the other at 1.59 ppm, corres-
ponding to the methylene protons. Upon complexation, the methine proton sig-
nals and the methylene proton signals from hydrogens at carbons 4, 6 and 10 
remain at the same chemical shift (as in the ligand), while the methylene proton 
signals from the hydrogens at carbons 2, 8 and 9 are shifted downfield, to 
1.66–1.70 ppm (adequate numeration is shown in Fig. 2). 
In the 13C-NMR spectra, there is an important downfield shift of the quat-
ernary carbon 1, from 47.2 ppm in the ligand to 48.8–50.1 ppm in the complex 
salts. This deshielding is the consequence of the electron-withdrawing effect of 
the silver(I) ion.  
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 Fig. 2. Numeration of 1-adamantanamine. 
Determination of MIC values was performed and all obtained complexes 
showed activity to the tested microorganisms. The antifungal activities are com-
parable with those of the test compound nystatin. Unfortunately, 1-adamantanamine 
is not soluble in water. Therefore, MIC values for the ligand were not determined.  
The diminished activity of the studied complexes (Table I) compared to 
simple silver(I) salts was expected, considering the lower concentration of free 
silver(I) ions due to complexation. On the contrary, only in one case, i.e. Asper-
gillus niger, MIC values determined for [Ag(1-AdNH2)2]CSA·2.5CH3OH 
showed significant increases in activity. Although the percentage of silver(I) in 
bis(1-adamantanamine)silver(I) D-camphor-10-sulphonate complex is lower than 
in nitrate and perchlorate analogues, [Ag(1-AdNH2)2]CSA·2.5CH3OH showed 
comparable activity in the case of Candida albicans. The increased activity of the 
camphorsulphonate complex was probably caused by the greater lipophilicity of 
the complex. 
























Streptomycin <0.001 0.019 0.019 >0.617 >0.617 
Nystatin – – – 5.399 2.483 
AgNO3 0.188 0.188 0.188 0.765 0.005 
AgClO4·H2O 0.124 0.244 0.124 0.124 0.124 
AgCSA 0.144 0.590 0.590 0.289 1.150 
[Ag(1-AdNH2)2]NO3·0.5CH3OH 0.471 31.962 31.962 31.962 31.962 
[Ag(1-AdNH2)2]ClO4·0.5CH3OH 29.420 29.420 29.420 29.420 4.393 
[Ag(1-AdNH2)2]CSA·2.5CH3OH 0.819 1.639 1.639 21.956 0.410 
The antiviral effect of adamantane amines is well known, as well as the anti-
bacterial effect of silver(I) ions.26 The demonstrated antifungal and antibacterial 
activities of the newly synthesized complex compounds may have significance 
for their further application. 
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CONCLUSIONS 
In this work, although being photosensitive, three novel compounds with a 
monodentate ligand, the almost completely rigid and bulky aliphatic amine 
(1-adamantanamine), were successfully prepared for the first time in a simple and 
low-cost way. All three compounds were characterized by atomic absorption, IR, 
and 1H- and 13C-NMR measurements. All three characterization methods evi-
denced that the complexation had been successfully achieved. Two characteristic 
bands that appear in the IR spectrum of the non-coordinated ligand became one 
broader peak positioned at higher energies in the spectra of the investigated com-
plexes. In the NMR spectra, important downfield shifts were observed upon 
complexation. Since this amine is a bulky and rigid monodentate ligand, and sil-
ver(I) mostly forms linear compounds, the obtained complexes had coordination 
number 2. It should be noted that in these compounds, the amine ligand is the 
sole electron donor. The measured antifungal and antibacterial activities of the 
synthesized compounds, may have an impact on their further applications as 
therapeutics. Special attention should be paid to the nitrate and perchlorate com-
plexes, although the lipophilic camphorsulphonate analogue gave satisfactory 
results despite having a lower percentage of silver(I). The obtained compounds 
are relatively unstable. However, these complexes could be observed as model 
systems in order to produce new derivatives with desired biological properties 
belonging to this class of compounds. 
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И З В О Д  
НОВА ЈЕДИЊЕЊА СРЕБРА(I) СА 1-АДАМАНТАНАМИНОМ 
ДЕЈАН ЈЕРЕМИЋ1, МИЛЕНА ЂОРЂЕВИЋ2, СРЂАН МИЛЕТИЋ3, ЉУБИЦА АНЂЕЛКОВИЋ4, ДУШАН СЛАДИЋ2 
и ИЛИЈА БРЧЕСКИ2 
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Његошева 12, 11000 Београд 
У овом раду су синтетисана три нова комплекса сребра(I) са јако ригидним и рела-
тивно великим монодентатним лигандом, 1-адамантанамином. Алифатични амин, 1-ада-
мантанамин, једини је електрондонорски лиганд у овим комплексима. Поред спектро-
скопске карактеризације, испитиване су и основне биолошке активности и одређене су 
минималне инхибиторне концентрације. Антифунгалне и антибактеријске активности 
ових једињења указују да она потенцијално могу бити примењења као нови терапеутици. 
(Примљено 14. новембра 2017, ревидирано 11. априла, прихваћено 16. априла 2018) 
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